Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 1381 AL 1395

Techniques to investigate neuronal mitochondrial function and its pharmacological modulation

Oliveira JM.

Curr Drug Targets. 2011 Jun;12(6):762-73. doi: 10.2174/138945011795528895.

Coexistence of TDP-43 and tau pathology in neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome)

Haraguchi T, Terada S, Ishizu H, Yokota O, Yoshida H, Takeda N, Kishimoto Y, Katayama N, Takata H, Akagi M, Kuroda S, Ihara Y, Uchitomi Y.

Neuropathology. 2011 Oct;31(5):531-9. doi: 10.1111/j.1440-1789.2010.01186.x. Epub 2011 Jan 30.

Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications

Cicchetti F, Soulet D, Freeman TB.

Brain. 2011 Mar;134(Pt 3):641-52. doi: 10.1093/brain/awq328. Epub 2011 Jan 28.

Pain and death: neurodegenerative disease mechanisms in the nociceptor

Reichling DB, Levine JD.

Ann Neurol. 2011 Jan;69(1):13-21. doi: 10.1002/ana.22351.

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial

Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fiévet MH, Bellanger A, Roze E, Meliksetyan G, Ben Djebara M, Hartmann A, Lacomblez L, Vrignaud C, Zahr N, Agid Y, Costentin J, Hulot JS, Vidailhet M.

Ann Neurol. 2011 Jan;69(1):111-8. doi: 10.1002/ana.22155.

Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis

Douville R, Liu J, Rothstein J, Nath A.

Ann Neurol. 2011 Jan;69(1):141-51. doi: 10.1002/ana.22149.

Is pathological gambling in Parkinson's disease reduced by amantadine?

Lee JY, Kim HJ, Jeon BS.

Ann Neurol. 2011 Jan;69(1):213-4; author reply 214-5. doi: 10.1002/ana.22289.

Caffeine and Parkinson's disease: are we getting our fix on risk-modifying gene-environment interactions?

Mellick GD, Ross OA.

Eur J Neurol. 2011 May;18(5):671-2. doi: 10.1111/j.1468-1331.2011.03350.x. Epub 2011 Jan 31.

Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non-inferiority trial

Constantinescu G, Theodoros D, Russell T, Ward E, Wilson S, Wootton R.

Int J Lang Commun Disord. 2011 Jan-Feb;46(1):1-16. doi: 10.3109/13682822.2010.484848.

Acute nicotine enhances strategy-based semantic processing in Parkinson's disease

Holmes AD, Copland DA, Silburn PA, Chenery HJ.

Int J Neuropsychopharmacol. 2011 Aug;14(7):877-85. doi: 10.1017/S1461145710001665. Epub 2011 Feb 1.

The pharmacokinetics and pharmacological effect of (S)-5-OH-DPAT following controlled delivery with transdermal iontophoresis

Ackaert OW, De Graan J, Shi S, Vreeken R, Pasqua OE, Dijkstra D, Westerink BH, Danhof M, Bouwstra JA.

J Pharm Sci. 2011 Jul;100(7):2996-3009. doi: 10.1002/jps.22492. Epub 2011 Jan 31.

Clinical problems in the hospitalized Parkinson's disease patient: systematic review

Gerlach OH, Winogrodzka A, Weber WE.

Mov Disord. 2011 Feb 1;26(2):197-208. doi: 10.1002/mds.23449. Epub 2011 Jan 31.

The management of Parkinson's disease - what is new?

Schapira AH.

Eur J Neurol. 2011 Mar;18 Suppl 1:1-2. doi: 10.1111/j.1468-1331.2010.03323.x.

Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release

Rascol O.

Eur J Neurol. 2011 Mar;18 Suppl 1:3-10. doi: 10.1111/j.1468-1331.2010.03326.x.

Treatment of depressive symptoms in Parkinson's disease

Barone P.

Eur J Neurol. 2011 Mar;18 Suppl 1:11-5. doi: 10.1111/j.1468-1331.2010.03325.x.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias